01/25/2021: Kardium announces $115M in new financing for innovative atrial fibrillation treatment

Fidelity Management & Research Company LLC and T. Rowe Price funds lead private financing round, which will accelerate commercial growth across Europe and enable a a clinical study for US Food and Drug Administration (FDA) approval.

11/11/2020: Kardium performs first cases with the Globe^® Positioning System

Kardium performs first cases with the Globe® Positioning System

09/08/2020: Kardium Marks First Commercial Procedures of Globe^® Mapping and Ablation System

Prof. Hans Kottkamp of Sana Hospital Benrath and Prof. Philipp Sommer of the Herz- und Diabeteszentrum NRW performed the first procedures with the Globe System.

08/05/2021: Kardium selected as Medical/Digital Technology Company of the Year

Life Sciences BC has selected Kardium Inc. as the Medical/Digital Technology Company of the Year.

07/20/2021: More precise and effective: Innovative catheter technology in the cardiac catheterization laboratory

Cardiologists at the RHÖN-KLINIKUM Campus Bad Neustadt apply state-of-the-art single catheter complete solution for the treatment of atrial fibrillation for the first time.

01/25/2021: B.C. heart device firm Kardium founded by Creo executives raises $115-million from Fidelity, T. Rowe Price ahead of going public

Kardium's Globe Mapping and Ablation System is intended to disrupt a roughly $6-billion market for treating atrial fibrillation, which is expected to grow by 15 per cent a year as Baby Boomers age.